Wells Fargo Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Edwards Lifesciences but lowers the price target from $90 to $80.
September 09, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo has maintained its Overweight rating on Edwards Lifesciences but has reduced the price target from $90 to $80, indicating a more cautious outlook.
The maintenance of an Overweight rating suggests continued confidence in the stock, but the lowered price target indicates a more cautious outlook, likely due to revised expectations or market conditions. This could lead to a short-term negative impact on the stock price as investors adjust to the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100